IPO9-AS1
gene geneOn this page
Summary
IPO9-AS1 (IPO9 antisense RNA 1, HGNC:40892) is a long non-coding RNA gene on chromosome 1q32.1.
At a glance
- Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:40892 |
| Approved symbol | IPO9-AS1 |
| Name | IPO9 antisense RNA 1 |
| Location | 1q32.1 |
| Locus type | RNA, long non-coding |
| Status | Approved |
| Ensembl gene | ENSG00000231871 |
| Ensembl biotype | lncRNA |
| Entrez | 100873949 |
| RNAcentral | URS000075CC49 — lncRNA, 842 nt, 1 organism(s) |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 3 lncRNA
ENST00000413035, ENST00000421159, ENST00000421449
RefSeq mRNA: 0 — MANE Select: None
Canonical transcript exons
ENST00000413035 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001646489 | 201688259 | 201688413 |
| ENSE00001657260 | 201817227 | 201817301 |
| ENSE00001706034 | 201828951 | 201829559 |
Expression profiles
Bgee: expression breadth ubiquitous, 134 present calls, max score 96.51.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.9361 / max 62.7453, expressed in 1279 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 16677 | 2.3453 | 1156 |
| 16678 | 0.5908 | 297 |
Top tissues by expression
136 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| quadriceps femoris | UBERON:0001377 | 96.51 | gold quality |
| cerebellar vermis | UBERON:0004720 | 95.83 | gold quality |
| thymus | UBERON:0002370 | 85.39 | silver quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 80.95 | gold quality |
| sural nerve | UBERON:0015488 | 80.73 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 80.58 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 72.99 | gold quality |
| bone marrow cell | CL:0002092 | 71.34 | silver quality |
| cortical plate | UBERON:0005343 | 66.41 | gold quality |
| ganglionic eminence | UBERON:0004023 | 65.92 | gold quality |
| calcaneal tendon | UBERON:0003701 | 64.40 | gold quality |
| apex of heart | UBERON:0002098 | 63.65 | gold quality |
| stromal cell of endometrium | CL:0002255 | 63.49 | gold quality |
| ventricular zone | UBERON:0003053 | 63.42 | gold quality |
| granulocyte | CL:0000094 | 62.02 | gold quality |
| monocyte | CL:0000576 | 61.91 | gold quality |
| leukocyte | CL:0000738 | 61.74 | gold quality |
| body of uterus | UBERON:0009853 | 61.59 | gold quality |
| myometrium | UBERON:0001296 | 60.92 | gold quality |
| right ovary | UBERON:0002118 | 60.59 | gold quality |
| bone marrow | UBERON:0002371 | 60.57 | gold quality |
| left ovary | UBERON:0002119 | 60.15 | gold quality |
| ovary | UBERON:0000992 | 59.99 | gold quality |
| placenta | UBERON:0001987 | 59.87 | gold quality |
| endocervix | UBERON:0000458 | 59.52 | gold quality |
| lymph node | UBERON:0000029 | 58.77 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 58.42 | gold quality |
| uterine cervix | UBERON:0000002 | 58.38 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 57.94 | gold quality |
| lower esophagus | UBERON:0013473 | 57.88 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-25 | yes | 18.22 |
| E-ANND-3 | no | 2.51 |
Regulation
Is transcription factor: no
Cross-species orthologs
0 orthologs
Protein
Non-coding RNA — no protein product; not a drug target.
Function
No curated pathway, Gene-Ontology, or interaction data.
Disease & clinical
No curated disease, variant, or cancer-driver associations.
Drugs & pharmacology
No drug or pharmacology data — not an established drug target.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.